Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

  |  

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. New release: GSK receives positive top-line results from sirukumab phase III program supporting regulatory filings for rheumatoid arthritis in 2016. 2015 Dec 16.
  2. Mease PJ, Collier DH, Saunders KC, et al. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: Results from the Corrona registry. RMD Open. 2015;1:e000181. doi:10.1136/rmdopen-2015-000181

Related Articles

    Sirukumab Promising for RA

    In a clinical trial, RA patients on sirukumab experienced decreased disease activity and improved physical function…

    Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis

    Sirukumab Promising for RA Sirukumab, an investigational human monoclonal antibody that selectively binds to the interleukin (IL) 6 cytokine, has completed a randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial (SIRROUND-T) in patients with rheumatoid arthritis (RA).1 During the trial, which took place between July 25, 2012, and Jan. 12, 2016, researchers randomized adult patients…

    Sirukumab Approval Stalls

    Citing safety concerns, the FDA Arthritis Advisory Committee voted against recommending approval of sirukumab for treating adults with RA…

    Pursue Remission

    Disease remission should be the goal for all rheumatologists treating childhood arthritis